Production (Stage)
GT Biopharma, Inc.
GTBP
$3.04
$0.020.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -54.56% | -20.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -48.66% | 4.41% | |||
| Operating Income | 48.66% | -4.41% | |||
| Income Before Tax | 79.44% | -10.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 79.44% | -10.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 79.44% | -10.67% | |||
| EBIT | 48.66% | -4.41% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 80.21% | -9.54% | |||
| Normalized Basic EPS | 54.75% | -9.44% | |||
| EPS Diluted | 80.21% | -9.54% | |||
| Normalized Diluted EPS | 54.75% | -9.44% | |||
| Average Basic Shares Outstanding | 3.88% | 1.04% | |||
| Average Diluted Shares Outstanding | 3.88% | 1.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||